Citations

Clear

111 citation(s) found for "Stevenson, L W".

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Stevenson, James, Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Dowell, Jonathan, Durm, Gregory A. , Gettinger, S., Grotz, Travis E., Gubens, Matthew A., Lackner, Rudy P., Lanuti, Michael, Levy, Benjamin, Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C., Ng, Thomas, Owen, Dawn , Owen, Dwight H., Patil, Tejas, Polanco, Patricio M., Riess, Jonathan, Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Tam, Alda, Yau, Edwin, Yun, Karen, Gregory, Kristina, Hang, Lisa, Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bauman, Jessica R. , Bharat, Ankit , Gettinger, Scott , Grotz, Travis E. , Gubens, Matthew A. , Juloori, Aditya , Levy, Benjamin , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Mullikin, Trey C. , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yau, Edwin , Yun, Karen M. , Gregory, Kristina M., Hang, Lisa E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0038 | PMID 42607715 Get It

Mesothelioma is a rare cancer that originates from the mesothelial surfaces of certain sites within the body. Pleural mesothelioma is the most common type and represents approximately 85% of mesotheliomas. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for evaluation and treatment in patients with pleural mesothelioma. The NCCN Guidelines will continue to be updated annually based on available clinical evidence and panel consensus.
Laparoscopic versus open surgery for rectal cancer: individual patient data meta-analysis of the ALaCaRT and Z6051 randomized trials
Stevenson, Andrew R L, Solomon, Michael J. , Murray, James, Wilson, Kate, Gebski, Val , Fleshman, James, Shi, Qian , Read, Thomas E. , Simes, John, Brown, Kilian G M , Solomon, Michael J , Gebski, Val , Shi, Qian , Brown, Kilian G. M. , Stevenson, Andrew R. L. , Simes, John

Mayo Clinic

BJS Open | July 5, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1093/bjsopen/zrag119 | PMID 42565372 Get It

Abstract Background The multicentre ALaCaRT and ACOSOG Z6051 randomized trials were unable to demonstrate non-inferiority of laparoscopic versus open surgery for rectal cancer with respect to a composite pathology metric indicating successful resection. Neither trial was individually powered to detect differences in long-term recurrence or survival. This planned meta-analysis determined long-term oncological outcomes of laparoscopic versus open proctectomy for rectal adenocarcinoma. Methods This prospective meta-analysis included individual patient data from patients with cT1–3 N0–2 M0 rectal adenocarcinoma enrolled in the ALaCaRT and ACOSOG Z6051 trials. Pathologically successful resection was defined as complete or near-complete total mesorectal excision, a clear circumferential resection margin (CRM; > 1 mm), and a clear distal resection margin (> 1 mm). The non-inferiority margin for disease-free survival (DFS) was an absolute difference of 5% at least 3 years after surgery. Results The combined data set included 935 patients (65.6% men, mean age 60.7 years, mean body mass index 26.7 kg/m2) randomized to open (457 patients) or laparoscopic (478 patients) proctectomy. Pathologically successful resection was lower in the laparoscopic than open group (85.1% versus 89.9%, respectively; pooled estimate 4.6% difference; 95% confidence interval (c.i.) −8.6% to −0.5%). The median follow-up was 60.2 (interquartile range 49.9–61.1) months. Three-year DFS was 75.2% (95% c.i. 71.1% to 79.2%) and 76.5% (95% c.i. 72.5% to 80.6%) for the laparoscopic and open groups, respectively (pooled estimate difference −1.5%; 95% c.i. −7.2% to 4.2%). Non-inferiority of laparoscopic surgery was not demonstrated because the lower one-sided 95% c.i. (−6.3% to 100%) crossed −5%. Three-year locoregional recurrence was higher in laparoscopic than open group (5.4% (95% c.i. 3.3% to 7.5%) versus 2.0% (95% c.i. 0.7% to 3.4%), respectively; pooled estimate 3.1% difference (95% c.i. 0.6% to 5.6%)). A clear CRM was the most significant and only pathological predictor of both DFS (P < 0.0001) and overall survival (P < 0.0001). Conclusion Laparoscopic proctectomy led to a lower rate of pathologically successful resection and a higher rate of locoregional recurrence at 3 years. The possibility of subsequent poorer DFS or overall survival rate requires further evaluation, because this analysis was not specifically powered for these endpoints.
Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.
Rotow, Julia K., Baik, Christina S., Dimou, Anastasios, Feng, Jamie, Gordon, Sarah , Chen, Haobin , Desai, Aakash, Niu, Jiaxin, Benyounes, Amin, Sankar, Kamya, Spira, A.I., Stevenson, James, Patel, Shetal , Halmos, Balazs, Shu, Catherine A., Le, Xiuning, Baik, Christina S. , Dimou, Anastasios , Nguyen, Danny , Niu, Jiaxin , Johnson, Melissa L. , Sankar, K. Nathan , Scott, Susan Combs , Stevenson, James, Halmos, Balazs , Shu, Catherine A. , Yu, Helena Alexandra , Le, Xiuning

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8519-8519

10.1200/jco.2026.44.16_suppl.8519 Get It

8519 Background: Non-classical mutations (NCM) of epidermal growth factor receptor (EGFR) represent a broad group of oncogenic mutations in non-small cell lung cancer (NSCLC), often associated with resistance to osimertinib (e.g., P-loop and αC-helix compressing [PACC] mutations). Patients (pts) with NCM have inferior clinical outcomes with a high incidence of CNS metastases (CNSm). Silevertinib (BDTX-1535) is a fourth-generation, covalent EGFR TKI with high CNS penetrance targeting both EGFR classical mutations and NCM. The antitumor activity and safety of silevertinib in pts with advanced NSCLC were evaluated in a Phase 2 trial (NCT05256290). Methods: Pts with advanced EGFR NCM NSCLC who received no prior systemic therapy were enrolled (Cohort 3) based on a local molecular test. Silevertinib 200 mg was administered orally once daily. The primary endpoint of objective response rate (ORR) was assessed using RECIST v1.1. CNS ORR was assessed using Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) in pts with no prior CNS therapy. Secondary endpoints include progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), and safety. Results: From February 2024 to July 2025, 43 pts with 35 unique NCMs (including 25 pts with PACC mutations) were enrolled in Cohort 3: median age 70.0 years, 72% female, 74% white, and 42% never smoked cigarettes. As of November 3, 2025, median follow-up was 7.2 months. ORR by RECIST v1.1 is shown in the table. Sixteen pts (37%) had CNSm, including 7 pts (16%) with measurable CNS disease. RANO-BM CNS response was 86% (n=6/7). Complete clearance of EGFR VAF ctDNA was observed in 21/26 (81%) evaluable pts. Serious treatment-related adverse events (TRAEs) were reported in 5 pts (12%), and 4 pts (9%) discontinued treatment due to TRAEs. The most common TRAEs included rash (19%, grade 3), diarrhea (19%, grade 3), stomatitis (9%, grade 3), and paronychia (5%, grade 3). While 77% of pts had a dose reduction, 19/22 (86%) patients with a radiographic response maintained or deepened their response after dose reduction, including all patients with CNS response. Conclusions: Silevertinib demonstrated robust antitumor activity in treatment-naïve pts with a broad spectrum of NCM EGFR driver mutations with high intracranial activity in pts with brain metastases. The safety profile was consistent with the known AEs of the EGFR TKI class. Clinical trial information: NCT05256290 . Data as of November 3, 2025 N ORR n (%) 95% CI DCR n (%) 95% CI ITT Population * 43 26 (60) (44.4, 75.0) 39 (91) (77.9, 97.4) PACC mutations 25 14 (56) (34.9, 75.6) 22 (88) (68.8, 97.5) Compound mutations † 16 11 (69) (41.3, 89.0) 15 (94) (69.8, 99.8) *No pts with classical (E746_A750del or L858R) mutations were enrolled. † Presence of ≥ 2 NCMs. As of December 27, 2025, the 6-month PFS rate was 86% overall and 80% in pts with CNSm; available PFS and DOR data will be presented.
Changes in upright haemodynamics preceding heart failure events and other hospitalizations
Zalawadiya, Sandip , Desai, Akshay S. , Borlaug, Barry A. , Kiernan, M., Bennett, Mosi, Brugts, Jasper J. , Klein, Liviu, Stevenson, Lynne W, Borlaug, Barry A , Desai, Akshay S , Brugts, Jasper Jan , Kiernan, Michael S. , Bennett, Mosi Kadin, Klein, Liviu , Stevenson, Lynne W.

Mayo Clinic

European Journal of Heart Failure | May 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag165 | PMID 42153484 Get It

Abstract Aims Trends in upright seated pulmonary artery pressure (PAP) with synchronous measurement of weight, blood pressure (BP), and heart rate (HR) have not been compared prior to heart failure events (HFE) and other causes of hospitalization during remote monitoring. Methods We analysed 24-month data from patients in the PROACTIVE-HF trial. Participants (N = 456) used the CordellaTM HF daily to measure seated PAP, weight, BP, and HR, all taken and transmitted within minutes. Events that were analysed included HFE, those potentially related to HF treatment (HF-TRE), and others (non-HFE). Parameters were trended from 60-days before (D-60) to 30-days after (D + 30) the day of the event (D = 0), and their concurrent changes were compared between D-60 and D = 0, and D = 0 and D + 30 using a mixed effects model. Results There were 196 HFE, 276 non-HFE, and 66 HF-TRE. Prior to HFE, average mean PAP (mPAP) increased from 27.8 ± 10.9 mmHg at D-60 to 32.6 ± 11.2 mmHg at D = 0 (P < .001), and decreased to 30.0 ± 12.4 mmHg at D + 30 (P = .001). Kinetics of mPAP before HFE differed by left ventricular ejection fraction (LVEF); mPAP rose by 3.4 ± 6.8 mmHg in 2 weeks before HFE in those with LVEF >40%, whereas a similar magnitude (3.1 ± 9.1 mmHg) of mPAP rise occurred over 6-weeks before HFE in those with LVEF ≤40%. No consistent changes in weight, SBP, or HR prior to HFE were observed (P > .05). Changes in vital signs but not mPAP were noted prior to HF-TRE and non-HFE. Conclusion Seated mPAP increased weeks in advance of HFE and vital signs did not change consistently before HFE. Differential kinetics of mPAP prior to HFE by the LVEF suggest that an uptrend in seated mPAP may need to be addressed more rapidly in those with LVEF>40%. Changes in vital signs with non-HFE and HF-TRE need further validation.
Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R. , Bharat, A., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Durm, Gregory A. , Gettinger, S., Gubens, Matthew A. , Lackner, Rudy P., Levy, B., Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn, Patil, Tejas, Riess, Jonathan W. , Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Stevenson, James, Tam, A. , Yau, Edwin , Gregory, Kristina, Hang, Lisa E., Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bharat, Ankit , Dowell, Jonathan E. , Gettinger, Scott , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Ng, Thomas, Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yun, Karen M. , Gregory, Kristina M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2026.0017 | PMID 41956107 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable biomarkers.
The GA4GH Categorical Variation Representation Specification: A Unified Computational Framework for Reasoning over Genomic Variant Categories
Puthawala, Daniel , Reardon, Brendan , Babb, Lawrence , Kuzma, Kori , Stevenson, James , Goar, Wesley , Dolin, Robert H , Freimuth, Robert R. , Procknow, Catherine, Pitel, Beth A. , Kundu, Parijat , Rampersad, Akash , Allen, Eliezer M Van, Babb, Lawrence , Kuzma, Kori , Stevenson, James S , Goar, Wesley A , Pitel, Beth A , Van Allen, Eliezer M , Wagner, Alex H , Freimuth, Robert R , Wagner, Alex H.

Mayo Clinic

No container title available | February 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.10.705161 | PMID 42094490 Get It

Abstract Categorical variants, or sets of genomic alterations constrained by shared properties, are pervasive across clinical, regulatory, and research domains in the biomedical ecosystem, yet their inconsistent and non-computable representation hinders data interoperability and clinical interpretation. We surveyed genomic knowledgebases spanning regulatory approvals and the biomedical literature and found that categorical variants underpin a substantial proportion of clinical genomics knowledge, but are largely described using incompatible bespoke models. To address this, we developed the GA4GH Categorical Variation Representation Specification (Cat-VRS), a constraint-based framework that provides a unified computable representation for both precise and intentionally broad categories across molecular and systemic variant domains. Cat-VRS enables harmonization of genomic knowledgebases, computable category-based search, and automated matching between assayed variants and categorical entities in clinical and research contexts. By providing a principled, extensible model for categorical variation, Cat-VRS enables computable reasoning over genomic variant categories and establishes a foundation for the standardized representation and exchange of genomic knowledge.
In vivo detectability of tau‐PET tracers in Alzheimer's disease
Cecile, Tissot, Rahmouni, Nesrine, Tsai, Hsin‐Yeh, Therriault, Joseph, Macedo, Arthur, Servaes, Stijn, Stevenson, J. K. M. ller, Ziontz, Jacob , Liu, Peiwei, Gordon, Brian A., Pascual, Belen, Lowe, Val J. , Soleimani‐Meigooni, David, Oh, Hwamee, Klunk, William E, Rosa‐Neto, Pedro, Jagust, William J., Pascoal, Tharick A, Baker, Suzanne L. , Tissot, Cécile , Rahmouni, Nesrine , Therriault, Joseph , Macedo, Arthur C. , Servaes, Stijn , Stevenson, Jenna , Lussier, Firoza Zubeida , Trudel, Lydia , Gordon, Brian A. , Pascual, Belén , Soleimani‐Meigooni, David N. , Oh, Hwamee , Klunk, William E. , Rosa-Neto, Pedro , Jagust, William J. , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106041 Get It

Abstract Background Tau‐PET tracers are essential for visualizing pathology in Alzheimer's (AD). High detectability to tau is crucial for early detection and monitoring of tau deposition. This study compares the noise to dynamic range ratio (NRR) of [ 18 F]FTP, [ 18 F]MK6240, [ 18 F]PI2620, and [ 18 F]RO948, cross‐sectionally and longitudinally. Methods 460 individuals from the HEAD study (23 cognitively unimpaired (CU) young, 249 CU old and 188 cognitively impaired) underwent [ 18 F]FTP and [ 18 F]MK6240 tau‐PET scans; 94 additionally received [ 18 F]PI2620 and [ 18 F]RO948. A subset of 28 individuals (15 CU and 13 CI) underwent [ 18 F]FTP and [ 18 F]MK6240 follow‐up scans (1.5 ± 0.1 years later). Annual change was measured as [(followup‐baseline)/time between scans]. Noise was calculated as the standard deviation (SD) of CU Aβ‐ participants aged ≤65 (SD CUAβ‐≤65 ). The dynamic range was calculated as the SD across all subjects (SD range ). A lower the NRR (=SD CUAβ‐≤65 /SD range ) indicates more detectability. Analyses were performed at both region‐of‐interest and voxel‐wise levels. Results Across the whole cohort, [ 18 F]MK6240 exhibited lower NRR than [ 18 F]FTP in all regions. Voxel‐wise, differences were most pronounced in the frontal medial temporal regions (Figure 1). Within the four‐tracers subset, [ 18 F]PI2620 and [ 18 F]FTP showed the highest NRR in Braak II, followed by [ 18 F]RO948 and [ 18 F]MK6240. In Braak IV‐VI, [ 18 F]MK6240 consistently demonstrated the lowest values, followed by [ 18 F]PI2620, [ 18 F]FTP and [ 18 F]RO948. Similarly, in metatemporal‐ROI and Braak III, [ 18 F]MK6240 remained the lowest, however followed by [ 18 F]FTP, [ 18 F]PI2620 and [ 18 F]RO948 (Figure 2). Lower [ 18 F]MK6240 NRR was due to larger SD range , while [ 18 F]FTP's lower values stemmed from smaller SD CUAβ‐≤65 . Conversely, high [ 18 F]PI2620 and [ 18 F]RO948 values are driven by larger SD CUAβ‐≤65 . Longitudinal analyses further confirmed that [ 18 F]MK6240 exhibited the lowest NRR across the entire brain, including AD‐related regions, with voxel‐wise differences mainly in the temporal and parietal lobes. Conclusion Tau‐PET tracers exhibit significant variability in detectability. [ 18 F]MK6240 consistently demonstrated lower NRR, implying better detectability across all regions, cross‐sectionally and longitudinally. Despite differences in NRR, [ 18 F]FTP, [ 18 F]RO948 and [ 18 F]PI2620 followed similar pattern. These results provide insights into the differential tracer detectability, helping guide their optimal use in detecting and tracking tau pathology. Ongoing follow‐up scans will further clarify longitudinal tracer detectability and its implications for tau progression in AD.
Longitudinal progression and harmonization of tau‐PET tracers
Ferreira, Pamela C.L., Povala, Guilherme, Amaral, Lívia , Tudorascu, Dana , Finn, Quentin, Rahmouni, Nesrine, Therriault, Joseph, Servaes, Stijn, Stevenson, Jenna , Macedo, Arthur C. , Masdeu, Joseph C. , Soleimani‐Meigooni, David, Fortea, Juan M., Lowe, Val J. , Oh, Hwamee , Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Bauer‐Negrini, Guilherme , Ferreira, Pâmela C.L. , Povala, Guilherme , Bellaver, Bruna , Lussier, Firoza Zubeida , Rahmouni, Nesrine , Therriault, Joseph , Servaes, Stijn , Masdeu, Joseph C , Soleimani‐Meigooni, David N. , Fortea, Juan , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105956 Get It

Abstract Background Tau‐PET tracers have been used to monitor the progression of Alzheimer's disease (AD). However, different tracers present distinct patterns of binding throughout the brain, challenging the harmonization of their findings. Leveraging the HEAD Study, the largest head‐to‐head study of tau‐PET tracers, we recently developed the Uniτ scale, which cross‐sectionally harmonizes Flortaucipir and MK6240 onto a universal tau‐PET measurement. Here, we provide a preliminary evaluation of the Uniτ scale's longitudinal performance in HEAD and two independent cohorts. Methods We assessed 422 individuals across the AD spectrum with longitudinal tau‐PET from three cohorts: HEAD [13 cognitively unimpaired (CU), 9 cognitively impaired (CI) individuals, scanned head‐to‐head with Flortaucipir and MK6240], ADNI [74 CU, 208 CI, tracer: Flortaucipir], and TRIAD [72 CU, 46 CI, tracer: MK6240]. Standardized uptake ratios (SUVRs) were harmonized to Uniτ using the Uniτ Ecosystem ( unitau.app ). Braak I‐II and the Meta‐Temporal regions were used as regions of interest. Annual tau‐PET uptake change was calculated, and the effect size was defined as the mean annual change divided by its standard deviation. Results In HEAD, annual change in tau‐PET uptake in Braak I‐II across CU and CI was only detectable in MK6240 (Figure 1A). However, both tracers detected significant annual changes in the Meta‐Temporal ROI for CI (Figure 1B). In both ADNI (Flortaucipir) and TRIAD (MK6240), changes in tau‐PET uptake in Braak I‐II regions were not significant (Figures 2‐3A). However, across all cohorts, the Meta‐Temporal ROI consistently showed detectable annual tau‐PET increases—most pronounced among CI—leading to larger effect sizes than in Braak I‐II (Figures 1‐3B). The Uniτ harmonization did not fundamentally alter the pattern of the findings. However, in ADNI (Flortaucipir), Uniτ yielded a slightly higher effect size than SUVR in CU for both Braak I‐II and Meta‐Temporal regions. Conclusion In this large longitudinal sample, our findings confirm that Flortaucipir and MK6240 can detect tau PET changes over time likely associated with the progression of tau tangle pathology. While MK6240 appears to show greater progression in CU, both tracers progress similarly in CI. Our data also suggested that Uniτ harmonized tau PET measurements maintain the longitudinal characteristics of each tau PET tracer for use in clinical trials.
Heterogeneous tau patterns in atypical AD are explained by connectivity‐associated tau progression
Bruin, Hannah de , Groot, Colin , (ADNI), Alzheimer's Disease Neuroimaging Initiative, Barthel, Henryk, Bischof, Gérard N. , Boon, Baayla D.C., Brendel, Matthias, Cash, David M, Day, Gregory S, Dickerson, Brad C., Dyck, Christopher H van, Flier, Wiesje M. van der, Fredericks, Carolyn , Fryer, Tim D. , Giessen, Elsmarieke van de, Gordon, Brian A., Radford, Jonathan Graff, Hansson, Oskar H., Höglinger, Günter U, Hönig, Merle C., Irwin, David J., Jones, P Simon, Josephs, Keith A., Katsumi, Yuta , Lee, Eddie B., Xiong, Chengjie , McGinnis, Scott M., Mecca, Adam P. , O'Brien, John T, O'Dell, Ryan S, Rabinovici, Gil D., Rahmouni, Nesrine, Rosa‐Neto, Pedro, Sabri, Osama, Schott, Jonathan M, Schroeter, Matthias L, Seeley, William W., Servaes, Stijn, Sintini, Irene , Smith, Ruben, Stevenson, Jenna , Strandberg, Olof, Therriault, Joseph, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip SJ., Whitwell, Jennifer L., Yong, Keir X X, O’Brien, John T. , Rabinovici, Gil D. , Day, Gregory S. , O'Brien, John Tiernan , Day, Gregory S , Xiong, Chengjie , Rabinovici, Gil D , Groot, Colin , Initiative, Alzheimer's Disease Neuroimaging, Blazhenets, Ganna , Boellaard, Ronald , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Dickerson, Brad C., Doering, Elena , Drzezga, Alexander E. , Dyck, Christopher H. van , Eimeren, Thilo van , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Hobbs, Diana A. , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Josephs, Keith A. , Joie, Renaud La , Lee, Eddie B, Malpetti, Maura , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Palleis, Carla , Perneczky, Robert , Phillips, Jeffrey S , Putcha, Deepti , Rahmouni, Nesrine , Rosa-Neto, Pedro , Rowe, James B. , Rullmann, Michael , Saur, Dorothee , Schildan, Andreas , Schott, Jonathan M. , Schroeter, Matthias L , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Stomrud, Erik , Therriault, Joseph , Visser, Denise , Weston, Philip S.J. , Whitwell, Jennifer L. , Wolk, David A. , Yong, Keir , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Alzheimer's & Dementia | January 7, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_104871 Get It

Abstract Background The link between regional tau load and clinical manifestation of Alzheimer's disease (AD) highlights the importance of characterizing spatial tau distribution. In typical (memory‐predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicenters. However, atypical (non‐amnestic‐predominant) AD variants with heterogeneous tau patterns provide a key opportunity to assess the universality of connectivity as a scaffold for tau progression. Method We included tau‐PET data from 320 subjects with atypical AD, characterized by highly heterogeneous tau patterns ( n = 139 posterior cortical atrophy/PCA‐AD; n = 103 logopenic variant primary progressive aphasia/lvPPA‐AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS‐AD) from 14 sites, with a subset of patients ( n = 78) having longitudinal tau‐PET data. As an independent sample, we further included regional post‐mortem tau stainings from 93 atypical AD patients from two sites ( n = 19 PCA‐AD, n = 32 lvPPA‐AD, n = 23 bvAD, n = 19 CBS‐AD). Gaussian mixture modeling was used to harmonize different tau‐PET tracers by transforming tau‐PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether 1) brain regions with stronger functional connectivity showed greater covariance in cross‐sectional and longitudinal tau‐PET and post‐mortem tau pathology, and 2) functional connectivity of tau‐PET epicenters and tau‐PET accumulation epicenters was associated with cross‐sectional and longitudinal tau patterns. Result Tau‐PET epicenters—defined as the 5% brain regions with the highest tau load—aligned with clinical variants, e.g. a posterior pattern in PCA‐AD (“visual AD”) and left‐hemispheric temporal predominance in lvPPA‐AD (“language AD”) (Figure 1). More strongly functionally connected regions showed correlated concurrent tau‐PET levels, which was confirmed with post‐mortem data (Figure 2). Moreover, the connectivity profile of tau‐PET epicenters and accumulation epicenters corresponded to tau‐PET progression patterns (Figure 3). Conclusion Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicenters, across all AD clinical variants. Since tau proteinopathy is a key driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant‐specific endpoints in clinical trials.